Brensocatib is a small molecule inhibitor of dipeptidyl peptidase 1 (DPP1) used to reduce neutrophilic inflammation associated with non-cystic fibrosis bronchiectasis (NCFB). Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation.
- Mechanism
- Curator reviewed · 6 references
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by a cycle of infection, inflammation, and lung tissue damage. Pharmacologic treatment of NCFB is targeted against dipeptidyl peptidase 1 (DPP1), a cysteine protease which plays a crucial role in the activation of pro-inflammatory neutrophil serine proteases (NSPs) during neutrophil maturation in the bone marrow - including cathepsin G (CatG), neutrophil elastase (NE) and proteinase 3 (PR3) - which are implicated in the pathogenesis of neutrophil-mediated NCFB inflammation. Brensocatib is a competitive, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). In cell-based assays, DPP1 inhibition by brensocatib reduces the activity of NSPs including neutrophil elastase, cathepsin G, and proteinase 3.
- Primary indication
- Brensocatib is indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older.Curator reviewed · 1 structured indication
- Formula / weight
- C23H24N4O4 · 420.469 g/mol (avg)
- First approval
- United States, 2025
- Also known as
- (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
- Code names
- AZD-7986 · INS-1007
- Brand names
Resolves to
AEXFXNFMSAAELR-RXVVDRJESA-NSMILESCN1C(=O)OC2=CC=C(C=C12)C1=CC=C(C[C@H](NC(=O)[C@@H]2CNCCCO2)C#N)C=C1What you can answer from here — as of September 12, 2026
Which drugs share a target with Brensocatib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account